Ειδήσεις: LEERINK PARTNERS | PXAI

Version	Description	Date
8.42	[ADDED SOURCE REGISTRY LIST VIEW]	04/03/2026 16:19
8.41	[LOCALIZED INDEX.PHP MENU AND MODALS TO US ENGLISH]	04/03/2026 16:11
8.40	[TRANSLATED FRONTEND TO US ENGLISH]	04/03/2026 16:10
8.41	[RESTORED DETAILED SOURCES VIEW (ARTICLES + EVENTS) IN US ENGLISH]	04/03/2026 15:50
8.41	[RESTORED DETAILED SOURCES VIEW (ARTICLES + EVENTS) IN US ENGLISH]	04/03/2026 15:46
8.40	[REVERTED TO STANDARD TABLE LAYOUT (US ENGLISH)]	04/03/2026 15:40
8.39	[FIXED DB CONNECTION SCOPE IN SOURCES LOGIC]	04/03/2026 15:38
8.38	[TRANSLATED SOURCES VIEW TO US ENGLISH]	04/03/2026 15:01
8.37	[FULL FRONTEND TRANSLATION (MENU, FEED, COMMENTS, TTS) TO US ENGLISH.]	04/03/2026 14:58
8.67	[MANUAL OVERRIDE OF GREEK MENU ITEMS]	04/03/2026 13:36
8.66	[NGINX OPTIMIZED MENU FIX]	04/03/2026 13:33
8.65	[FIXED GREEK MENU ITEMS]	04/03/2026 13:32
8.60	[MENU & UI LOCALIZATION TO US ENGLISH]	04/03/2026 13:30
8.50	[FULL TRANSLATION TO US ENGLISH]	04/03/2026 13:27
9.75	[INJECTED EVENT FUSION_SUMMARY INTO FEED LOOPS TO DISPLAY AI TAGS CORRECTLY]	26/02/2026 14:44

24/03 18:55 defenseworld.net

Zura Bio (NASDAQ:ZURA) Price Target Raised to $11.00 at Chardan Capital

Zura Bio price target analyst ratings Chardan Capital Wedbush Oppenheimer

24/03 18:35 defenseworld.net

Mirum Pharmaceuticals (NASDAQ:MIRM) Receives Buy Rating from HC Wainwright

Mirum Pharmaceuticals buy rating price objective HC Wainwright Evercore Cantor Fitzgerald

20/03 08:24 defenseworld.net

Inventiva (NASDAQ:IVA) Coverage Initiated by Analysts at Truist Financial

Inventiva NASDAQ:IVA Truist Financial Leerink Partners HC Wainwright Weiss Ratings

20/03 07:54 defenseworld.net

Protagonist Therapeutics (NASDAQ:PTGX) Shares Up 4.6% on Analyst Upgrade

Protagonist Therapeutics stock price analyst upgrade Leerink Partners HC Wainwright Barclays

19/03 09:22 defenseworld.net

Trevi Therapeutics’ (TRVI) Buy Rating Reaffirmed at D. Boral Capital

Trevi Therapeutics buy rating target price biotech D. Boral Capital Leerink Partners

17/03 08:58 defenseworld.net

Oruka Therapeutics (NASDAQ:ORKA) Price Target Raised to $86.00 at Leerink Partners

Oruka Therapeutics target price Leerink Partners BTIG Barclays Wedbush

17/03 08:04 defenseworld.net

Design Therapeutics Maps H2 Data Readouts for RESTORE-FA, FECD Biomarker Study and DM1 Program

Design Therapeutics Friedreich’s ataxia frataxin restoration FECD biomarker DM1 preclinical RESTORE‑FA

17/03 08:04 defenseworld.net

Design Therapeutics Maps H2 Data Readouts for RESTORE-FA, FECD Biomarker Study and DM1 Program

Design Therapeutics Friedreich’s ataxia frataxin restoration FECD biomarker DM1 preclinical RESTORE‑FA

Loading...